Drug Type Synthetic peptide |
Synonyms Human c-peptide, Human proinsulin c-peptide, Insulin c-peptide + [4] |
Target |
Action stimulants |
Mechanism NOS stimulants(Nitric oxide synthase stimulants) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC129H211N35O48 |
InChIKeyVOUAQYXWVJDEQY-QENPJCQMSA-N |
CAS Registry33017-11-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 2 | Sweden | 01 Oct 2003 | |
Diabetic peripheral neuropathy | Phase 2 | Sweden | 01 Oct 2003 | |
Diabetic Neuropathies | Phase 2 | - | - |
Not Applicable | Diabetes Mellitus C-peptide | 270 | (C-peptide >200 pmol/L) | rachysediu(zhenxxsqyk) = ufxlvksstf gnplnmsfxq (untikrkpog ) View more | Positive | 03 Oct 2023 | |
(C-peptide > 600 pmol/L) | rachysediu(zhenxxsqyk) = swzfbrceit gnplnmsfxq (untikrkpog ) | ||||||
Not Applicable | - | bqbsmcyjqh(xzyfnekoff) = fqihxolbls rjyjkxdfmp (kdwksrfruo ) View more | - | 03 May 2021 | |||
Not Applicable | - | cmswufjwam(zbkwnchjgh) = mdeuackown siwviyrqaq (vjttmezhqh ) View more | - | 11 Nov 2014 |